1h Free Analyst Time
The active pharmaceutical ingredient (API) market in the US is forecasted to grow by USD 25.45 billion during 2024-2029, accelerating at a CAGR of 9% during the forecast period. The report on the active pharmaceutical ingredient (API) market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of type ii drug master files (DMF), growing prevalence of chronic conditions, and increasing demand for biopharmaceuticals and biosimilars.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The active pharmaceutical ingredient (API) market in the US is segmented as below:
By Type
- Captive API
- Contract API
By Product
- Generic
- Innovative
By Application
- Oncology
- Cardiovascular diseases
- Diabetes
- Communicable diseases
- Others
The report on the active pharmaceutical ingredient (API) market in the US covers the following areas:
- Active Pharmaceutical Ingredient (API) Market in the US sizing
- Active Pharmaceutical Ingredient (API) Market in the US forecast
- Active Pharmaceutical Ingredient (API) Market in the US industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Product
10 Market Segmentation by Application
11 Customer Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the active pharmaceutical ingredient (API) market in us: AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Inc., Dr Reddys Laboratories Ltd., DSM-Firmenich AG, GlaxoSmithKline Plc, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is paradigm shift in api manufacturing."
According to the report, one of the major drivers for this market is the increasing number of type ii drug master files (DMF).
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Bristol Myers Squibb Co.
- Cadila Pharmaceuticals Ltd.
- Cambrex Corp.
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- DSM-Firmenich AG
- GlaxoSmithKline Plc
- Lupin Ltd.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Viatris Inc.
